Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

Eli Lilly (NYSE:LLY) has become the industry leader in a class of drugs called glycogen-like peptide-1 therapies, or GLP-1, that were ... for over 150 years, a buy? Weight-loss drugs like Novo ...

The nature of the beast is yes, these drugs come off patent; the demand is there and someone could produce it more cheaply’, ...

That's how many people living in the United States have taken some form of a glucagon-like peptide 1, otherwise known as a GLP-1 ... We know that many people who buy our smoothies love to ...

"We see opportunity within our unique snacking portfolio," Tom McGough, co‐chief operating officer with Conagra Brands, told analysts at the Consumer Analyst Group of New York conference in Florida in ...

While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...

Individual plans that are compliant with the Affordable Care Act and are purchased on Healthcare.gov or through a local agent in North Dakota include coverage for glucagon-like peptide-1 (GLP-1 ...

The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics ...

The biggest talking point in the pharmaceutical industry at the moment revolves around treatments known as glucagon-like peptide-1 (GLP-1 ... is an opportunity to buy the dip, or run for the ...